Malte von Bonin

Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation

Antonio Galleu, Yanira Riffo‐Vasquez, Cristina Trento et al. · Science Translational Medicine · 2017 · 630 citations · Full text

Cell Therapy, Apoptosis, Immunology +18

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Armin Ehninger, Michael Krämer, Christoph Röllig et al. · Blood Cancer Journal · 2014 · 344 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Immunotherapy +17

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Thomas Illmer, Markus Schaich, Uwe Platzbecker et al. · Leukemia · 2004 · 306 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10